Crizotinib (PF-02341066)

Licensed by Pfizer Catalog No.S1068

Crizotinib (PF-02341066) Chemical Structure

Molecular Weight(MW): 450.34

Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.

Size Price Stock Quantity  
In DMSO USD 220 In stock
USD 110 In stock
USD 170 In stock
USD 570 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 65 Publications

8 Customer Reviews

  • (c) Western blot analyses of p-Akt (Ser473) and p-S6RP (Ser235 and Ser236) in two RCT-E565 transplanted tumors treated with vehicle or PF02341066. Samples were isolated 4 h after the last dose from mice treated with PF02341066 for 3 d. (d) Responses of RCT-E565 transplanted tumors in athymic mice to PF02341066 or vehicle. Data are means ±s.e.m. (each group, n = 6). *P < 0.005, **P < 0.001 (Student,s t test).

    Nat Med 2011 17, 1116-1120. Crizotinib (PF-02341066) purchased from Selleck.

    Ba/F3 cells grown in the presence of IL-3, or Ba/F3 cells expressing native EML4-ALK (clone #2, #10, #101, and #155) and EML4-ALK L1196M (clone #216, #302, #303, and #355), were treated with CH5424802 or PF-02341066 for 48 hr, and then the viable cells were measured by the Cell Titer-Glo Luminescent Cell Viability Assay. IC50 values were determined by plotting the drug concentration versus percentage of cell growth inhibition. Data are shown as mean ±SD (n = 3).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

  • Mice bearing Ba/F3-EML4-ALK (clone #10) and EML4-ALK L1196M (clone #303) were administered vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg) orally once daily for 8 days. Tumor volume for each dose group was measured. Data are shown as mean ± SD (n = 5). Parametric Dunnett’s test: ***p < 0.001; N.S., not significant, versus vehicle treatment at final day. For pharmacodynamic assay, mice bearing Ba/F3-EML4-ALK (clone #10) and -EML4-ALK L1196M (clone #303) were orally administered at single dose of vehicle, CH5424802 (60 mg/kg), or PF-02341066 (100 mg/kg), and the tumors were collected and lysed at 4 hr post-dosing. STAT3 and phosphorylated STAT3 (Tyr 705) were detected by immunoblot analysis using antibodies against each of them (n = 2 per group).

     

     

    Cancer Cell 2011 19, 679–690. Crizotinib (PF-02341066) purchased from Selleck.

    (A) VimPro-Fluc activity in spheroids after 72-h treatment with control modulators of epithelial-mesenchymal transition (EMT) normalized to spheroid viability and compared to vimentin protein expression using Western blot analysis. (B) Dose-response curves for both U0126 and axitinib control modulators of EMT. RLU, relative luminescence units.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

  • Secondary assay development. The invasive potential of MDA-MB-231 spheroids was measured using modified Boyden chambers coated with Matrigel™. Invading cells were fixed, stained with DAPI, and quantified by fluorescence microscopy using 5 random fields per filter insert in triplicate. U0126, PF2341066, axitinib, and PKC412 inhibited the invasive potential of MDA-MB-231 spheroids by ~90% as compared to untreated spheroids (UT). ***p ≤ 0.001. IGF1R and dasatinib displayed no statistical difference as compared to UT MDA-MB-231 spheroids.

    J Biomol Screen 2011 16, 141-154. Crizotinib (PF-02341066) purchased from Selleck.

    Inhibition of signaling pathway activation in lung tumor cell lines by kinase inhibitors. Lung tumor cells were cultured in 10% FBS until reaching ∼80% confluence and then the cells were starved in serum-free medium for overnight, followed by 4-hour treatment with the inhibitors. Cell lysates were then prepared and used for determination of the pathway activation signals by the CEER assay.

    Int J Proteomics 2011 2011, 215496. Crizotinib (PF-02341066) purchased from Selleck.

  • Inhibition of anchorage-independent growth of lung tumor cell lines by selected inhibitors. Each selected cell line was treated with the indicated inhibitor at 0.1 μM and 1 μM concentrations for two weeks and cell colony size formation was scored under the Nikon inverted-phase microscope.

    Int J Proteomics 2011 2011, Article ID 215496. Crizotinib (PF-02341066) purchased from Selleck.

    Western blot analysis of c-Met, MAPK and Akt. 0-100nM PF2341066 was added.

     

     

    Dr. Zhang of Tianjin Medical University. Crizotinib (PF-02341066) purchased from Selleck.

Purity & Quality Control

Choose Selective c-Met Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description Crizotinib (PF-02341066) is a potent inhibitor of c-Met and ALK with IC50 of 11 nM and 24 nM in cell-based assays, respectively.
Targets
c-Met [1]
(A549, MDA-MB-231, GTL-16, HT29, 786-O, Colo-205, A498 cells)
ALK [1]
(Karpas299 cells)
11 nM 24 nM
In vitro

PF-2341066 displays similar potency against c-Met phosphorylation in mIMCD3 mouse or MDCK canine epithelial cells with IC50 of 5 nM and 20 nM, respectivly. PF-2341066 shows improved or similar activity against NIH3T3 cells engineered to express c-Met ATP-binding site mutants V1092I or H1094R or the P-loop mutant M1250T with IC50 of 19 nM, 2 nM and 15 nM, respectively, compared with NIH3T3 cells expressing wild-type receptor with IC50 of 13 nM. In contrast, a marked shift in potency of PF-2341066 is observed against cells engineered to express c-Met activation loop mutants Y1230C and Y1235D with IC50 of 127 nM and 92 nM, respectively, compared with wild-type receptor. PF-2341066 also potently prevents the phosphorylation of c-Met in NCI-H69 and HOP92 cells, with IC50 of 13 nM and 16 nM, respectively, which express the endogenous c-Met variants R988C and T1010I, respectively. PF-2341066 is >1,000-fold selective for the VEGFR2 and PDGFRβ RTKs, >250-fold selective for IRK and Lck, and ∼40- to 60-fold selective for Tie2, TrkA, and TrkB, all compared with c-Met. PF-2341066 is 20- to 30-fold selective for RON and Axl RTKs. In contrast, PF-2341066 shows a near-equivalent IC50 of 24 nM against the nucleophosmin (NPM)-anaplastic lymphoma kinase (ALK) oncogenic fusion variant of the ALK RTK expressed by the KARPAS299 human anaplastic large cell lymphoma (ALCL) cell line. PF-2341066 inhibits c-Met–dependent neoplastic phenotypes of cancer cells and angiogenic phenotypes of endothelial cells. PF-2341066 suppresses human GTL-16 gastric carcinoma cell growth with IC50 of 9.7 nM. PF-2341066 induces apoptosis in GTL-16 cells with IC50 of 8.4 nM. PF-2341066 inhibits HGF-stimulated human NCI-H441 lung carcinoma cell migration and invasion with IC50 of 11 nM and 6.1 nM, respectively. PF-2341066 inhibits MDCK cell scattering with IC50 of 16 nM. PF-2341066 prevents HGF-stimulated c-Met phosphorylation, cell survival, and Matrigel invasion with IC50 of 11 nM, 14 nM and 35 nM, respectively. In addition, PF-2341066 prevents serum-stimulated HMVEC branching tubulogenesis (formation of vascular tubes) in fibrin gels. [1] PF-2341066 also potently inhibits NPM-ALK phosphorylation in Karpas299 or SU-DHL-1 ALCL cells with an IC50 of 24 nM. PF-2341066 potently prevents cell proliferation, which is associated with G(1)-S-phase cell cycle arrest and induction of apoptosis in ALK-positive ALCL cells with IC50 of 30 nM, but not ALK-negative lymphoma cells. [2] Besides, PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (i.e., proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
BAF3 MV;DfZRwfG:6aXOgRZN{[Xl? M1y5RVQ5KGh? M1vWWGROW09? NFrFdlhEgXSxdH;4bYNqfHliYXfhbY5{fCCvb4Xz[UBDSUZ|IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRiY3;lfJBz\XO|aX7nJGVOVDRid3n0bEBKSzVyIH;mJFAvPjJizszN NV7GcFZCOjF3N{K1PFk>
BAF3 NIfFUZFEgXSxdH;4bYMhSXO|YYm= MnPqOFghcA>? NHzXOplFVVOR M13wc2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCTjNiY3XscJMh\XiycnXzd4lv\yCDTFugUFEyQT[PIH31eIFvfCClb3X4dJJme3OrbnegSW1NPCC5aYToJGlEPTBib3[gNk4zKM7:TR?= NWntN41POjF3N{K1PFk>
BAF3 NHXDWFhEgXSxdH;4bYMhSXO|YYm= M3vTUFQ5KGh? NYLsU|ZDTE2VTx?= MVjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRWY{KGOnbHzzJIV5eHKnc4PpcochTU2OND3BUGshf2m2aDDJR|UxKG:oIECuNlgh|ryP NX;WbGZiOjF3N{K1PFk>
Kelly MVnDfZRwfG:6aXOgRZN{[Xl? MX\EUXNQ M3;LPGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGtmdGy7IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPDJizszN NI\hNGEzOTV5MkW4PS=>
SH-SY5Y NULjW5BmS3m2b4TvfIlkKEG|c3H5 MXHEUXNQ MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDTTE1UYTW\IHPlcIx{KGW6cILld5NqdmdiQVzLJGYyOTd2TDDteZRidnRid3n0bEBKSzVyIH;mJFAvPTNizszN MofBNlE2PzJ3OEm=
SMS-KCN NVzubWlqS3m2b4TvfIlkKEG|c3H5 NFnD[ItFVVOR NXnheXl5S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hW02VLVvDUkBk\WyuczDlfJBz\XO|aX7nJGFNUyCUMUK3OXEhdXW2YX70JJdqfGhiSVO1NEBw\iByLkmxJO69VQ>? NIjkZ2IzOTV5MkW4PS=>
BAF3 NEDjUZlEgXSxdH;4bYMhSXO|YYm= NUPUTZNIPDhiaB?= NXfidHBMTE2VTx?= NUXKfZRIS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhSkGIMzDj[YxteyCneIDy[ZN{cW6pIGTlcE1CVEtid3n0bEBKSzVyIH;mJFAvOTlizszN M1fxPVIyPTd{NUi5
3T3 NUG0VpRzTnWwY4Tpc44hSXO|YYm= MorkNUBp NYPXXIR4TE2VTx?= MorGTY5pcWKrdHnvckBw\iCUT16gZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwMEig{txO MXKyNVgyOjRzNB?=
3T3-E NHfZNZdHfW6ldHnvckBCe3OjeR?= NWTn[VdLOSCq NVfEbYs6TE2VTx?= NHviZ5RKdmirYnn0bY9vKG:oIGTJSVIh[XO|ZYPz[YQh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDBwNES4JO69VQ>? MXmyNVgyOjRzNB?=
A549 NIrx[I5McW6jc3WgRZN{[Xl? MUSxJIg> M2jCcWROW09? M{fhbmlvcGmkaYTpc44hd2ZiaIXtZY4hemWlb33ibY5idnRiYz3NSXQhc2mwYYPlJIV5eHKnc4Pl[EBie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJGhITi2rbnT1Z4VlKGG3dH;wbI9{eGixconsZZRqd25id3n0bEBKSzVyIH;mJFAvODB6IN88US=> M{nMdFIyQDF{NEG0
BAF3-BCL NHSxTJhHfW6ldHnvckBCe3OjeR?= NH[ze3AyKGh? M2\1RWROW09? M2PVPWlvcGmkaYTpc44hd2ZiQVLMJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iBzLkG1PUDPxE1? NF;FPGozOThzMkSxOC=>
HEK293 NEnhdGZHfW6ldHnvckBCe3OjeR?= MXWxJIg> NIDxZlBFVVOR NFfZfY5KdmirYnn0bY9vKG:oIFHYUEBie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6yPVQh|ryP MoTRNlE5OTJ2MUS=
HEK293 MV3GeY5kfGmxbjDBd5NigQ>? NWPoZXBsOSCq MYXEUXNQ M1uzVGlvcGmkaYTpc44hd2ZiSWKgZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwOEi3JO69VQ>? MUOyNVgyOjRzNB?=
Jurkat MXPGeY5kfGmxbjDBd5NigQ>? MoX4NUBp MXLEUXNQ MljSTY5pcWKrdHnvckBw\iCOQ1ugZZN{\XO|ZXSgZZMh\3Kxd4ToJIZi[3Sxcj3pcoR2[2WmIHH1eI9xcG:|cHjvdplt[XSrb36ge4l1cCCLQ{WwJI9nKDJwN{SxJO69VQ>? MmfpNlE5OTJ2MUS=
KARPAS299 NHnIWYdMcW6jc3WgRZN{[Xl? MmG1NUBp MV7EUXNQ NHfJTI9KdmirYnn0bY9vKG:oIFHMT{Bie3Onc4Pl[EBieyCpcn;3eIgh\mGldH;yMYlv\HWlZXSgZZV1d3Cqb4PwbI9zgWyjdHnvckB4cXSqIFnDOVAhd2ZiMD6wNkDPxE1? Ml63NlE5OTJ2MUS=
PAE MoH3SpVv[3Srb36gRZN{[Xl? M{TJelEhcA>? M2\oOmROW09? MmTPTY5pcWKrdHnvckBw\iCWUlvCJIF{e2W|c3XkJIF{KGe{b4f0bEBn[WO2b4KtbY5lfWOnZDDheZRweGixc4Doc5J6dGG2aX;uJJdqfGhiSVO1NEBw\iByLkO5PUDPxE1? MWGyNVgyOjRzNB?=
BAF3 M2fDSWZ2dmO2aX;uJGF{e2G7 NGXjcXIzNTNiZB?= NHrw[YRFVVOR Mnv6TY5pcWKrdHnvckBw\iCWRVyt[pV{\WRiaX7zeYxqdiC{ZXPldJRweiCneIDy[ZN{\WRid3n0bEBKSzVyIH;mJFEvPjR|IN88US=> MV:yN|c1OjJ3Mh?=
KARPAS299 Mk\4R5l1d3SxeHnjJGF{e2G7 NF3xdGQzNTNiZB?= M4\yVGROW09? NVHMVpdPUUN3ME2wMlA3PDJizszN M2T3fVI{PzR{MkWy
EBC1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TyRlczKGh? NH3jd4tFVVOR Mn\nTWM2OD1yLkCyN{DPxE1? M1;nPVI{QTl|M{K4
HCT116 M2j1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV63NkBp MlS3SG1UVw>? NE\6RmFKSzVyPUG0MlgzKM7:TR?= MmjoNlM6QTN|Mki=
MCF7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHIdXE5PzJiaB?= MoHHSG1UVw>? MWPJR|UxRTlwNUig{txO MmnwNlM6QTN|Mki=
MDA-MB-231 M3T6bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GxOFczKGh? M2rZRmROW09? NVPYR3FGUUN3ME2xNE45KM7:TR?= MWeyN|k6OzN{OB?=
MKN45 NED3XVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWOzcXA5PzJiaB?= M2PQSmROW09? NW\rVVdZUUN3ME2wMlAyOyEQvF2= MlrlNlM6QTN|Mki=
NCI-H441 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHqR2o4OiCq M2LWRmROW09? NIPBSWRKSzVyPUG3MlI2KM7:TR?= MVmyN|k6OzN{OB?=
NCI-H661 NInvT2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXvX[oEzPzJiaB?= MXPEUXNQ MlO2TWM2OD1zMT60O{DPxE1? NYf5b2dkOjN7OUOzNlg>
SK-MEL-28 NHjVOYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnkUFdXPzJiaB?= NVLvUnZVTE2VTx?= MWTJR|UxRTFyLkm3JO69VQ>? NF3QbYQzOzl7M{OyPC=>
SKOV3 M4\L[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF6xfWI4OiCq NIC3UFBFVVOR NH;v[GpKSzVyPUGyMlg2KM7:TR?= NFrBZWczOzl7M{OyPC=>
SNU5 M1PlVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYe2V3RFPzJiaB?= M4nJNmROW09? M2LHemlEPTB;MD6wNVYh|ryP NH[1SVEzOzl7M{OyPC=>
NCI-H2228 NX2y[mpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUXtVXQ3PzJiaB?= NH63O|ZFVVOR Mn;nTY5pcWKrdHnvckBw\iCDTFut[pV{cW:wIHTybZZmdiClZXzsJJBzd2yrZnXyZZRqd25id3n0bEBKSzVyIH;mJFAvOTF6IN88US=> M{LYOlI1PDN{OUC5
NCI-H3122 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TDZVczKGh? MnfQSG1UVw>? NHPD[YpKdmirYnn0bY9vKG:oIFHMT{1nfXOrb36g[JJqfmWwIHPlcIwheHKxbHnm[ZJifGmxbjD3bZRpKEmFNUCgc4YhOC5zMEig{txO M2HkZlI1PDN{OUC5
NCI-H3122 M{W4bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLuO|IhcA>? MnrpSG1UVw>? NWXDSoNuUW6qaXLpeIlwdiCxZjDBUGsu\nW|aX;uJIRzcX[nbjDj[YxtKHC{b3zp[oVz[XSrb36gbY4hcHWvYX6gUmNKNUh|MUKyJINmdGy|IHjhdoJwemmwZzDBUGshTzF{NknBJI12fGGwdDD3bZRpKEmFNUCgc4YhOC54MkOg{txO Mn;hNlQ1OzJ7MEm=
NCI-H3122 NEfKPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\4VFczKGh? MnLkSG1UVw>? MULJcohq[mm2aX;uJI9nKEGOSz3meZNqd25iZILpeoVvKGOnbHygdJJwdGmoZYLheIlwdiCrbjDoeY1idiCQQ1mtTFMyOjJiY3XscJMhcGG{Yn;ybY5oKEGOSzDMNVE6Pk1ibYX0ZY51KHerdHigTWM2OCCxZjCwMlg{QCEQvF2= M2HEUVI1PDN{OUC5
NIH-3T3 M1z5[GtqdmG|ZTDBd5NigQ>? Ml;QNUBp Mn7ESG1UVw>? MnHzTY5pcWKrdHnvckBw\iCqdX3hckB4cWymIIT5dIUhTU2OND3meZNm\CCDTFug[ZhxemW|c3XkJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD6wPEDPxE1? NYO0TGVtOjR2M{K5NFk>
NIH-3T3 NHOwWopMcW6jc3WgRZN{[Xl? NFHvOpgyKGh? M1XKVmROW09? NWOxbG5OUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJ4OVGgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD62NFUh|ryP MUGyOFQ{OjlyOR?=
NIH-3T3 NGDBPGhMcW6jc3WgRZN{[Xl? M3H0eFEhcA>? M3zrOWROW09? M4Hr[WlvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugV|EzOD[\IH31eIFvfCCneIDy[ZN{\WRiYYPz[ZN{\WRiYYOgdIhwe3Cqbz3BUGshdGW4ZXyge4l1cCCLQ{WwJI9nKDBwNkK2JO69VQ>? NWToUFhqOjR2M{K5NFk>
NIH-3T3 MnHXT4lv[XOnIFHzd4F6 MYCxJIg> M2Drd2ROW09? NWf6PFk{UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF7Nl2gcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMD64OFMh|ryP NImweHIzPDR|MkmwPS=>
NIH-3T3 NFm0RWxMcW6jc3WgRZN{[Xl? NV65bnM4OSCq NUTQSlRNTE2VTx?= NXT5fYpwUW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BNOTF3MmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6wNlYh|ryP NVzHPXVwOjR2M{K5NFk>
BAF3 M2TUNGZ2dmO2aX;uJGF{e2G7 M3i0WFczKGh? NEPjfHJFVVOR NFvGUnlKdmirYnn0bY9vKG:oIF7QUU9CVEtidILhcpNn\WO2ZXSgZZN{\XO|ZXSgZZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD3bZRpKEmFNUCgc4YhOC5yNUGg{txO Mn3lNlQ1Pjh4M{K=
BAF3 MnH5R5l1d3SxeHnjJGF{e2G7 NXPxUXZTPzJiaB?= NWf1OZdqTE2VTx?= NXXqVJFTUUN3ME2wMlk5KM7:TR?= NHPIbpczPDR4OE[zNi=>
NIH-3T3 NHfDZ2FMcW6jc3WgRZN{[Xl? NYf3bGxCOSCq MomwTY5pcWKrdHnvckBw\iCqdX3hckBGVUx2LX\1d4VlKEGOSzDGNVE4PExibYX0ZY51KGW6cILld5Nm\CCjc4Pld5Nm\CCjczDwbI9{eGixLVHMT{Bt\X[nbDD3bZRpKEmFNUCgc4YhOC5zNkWg{txO MWKyOFgyQTFzNh?=
NIH-3T3 MUnLbY5ie2ViQYPzZZk> MW[xJIg> MVnJcohq[mm2aX;uJI9nKGi3bXHuJGVOVDRvZoXz[YQhSUyNIFOxNVU3YSCvdYThcpQh\XiycnXzd4VlKGG|c3Xzd4VlKGG|IIDoc5NxcG9vQVzLJIxmfmWuIIfpeIghUUN3MDDv[kAxNjR5ODFOwG0> NFX0dJczPDhzOUGxOi=>
NIH-3T3 MV3LbY5ie2ViQYPzZZk> NYXOZlFMOSCq NXnCe2x5UW6qaXLpeIlwdiCxZjDoeY1idiCHTVy0MYZ2e2WmIFHMT{BIOTJyMmKgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMT6xOFgh|ryP NUHGe2JCOjR6MUmxNVY>
NIH-3T3 MXPLbY5ie2ViQYPzZZk> MWmxJIg> M4nDO2lvcGmkaYTpc44hd2ZiaIXtZY4hTU2OND3meZNm\CCDTFugNVE2OVSrboOgcZV1[W62IHX4dJJme3OnZDDhd5Nme3OnZDDhd{BxcG:|cHjvMWFNUyCuZY\lcEB4cXSqIFnDOVAhd2ZiMz6wN|kh|ryP M1LIU|I1QDF7MUG2
KARPAS299 MmfkT4lv[XOnIFHzd4F6 M1;leFkxKG2rbh?= M1nPdWROW09? MkTpTY5pcWKrdHnvckBw\iCQUF2t[pV{\WRiQVzLJJBpd3OyaH;yfYxifGmxbjDlfJBz\XO|ZXSge4l1cCCLQ{WwJI9nKDBwMUGg{txO NHzJW2wzPDlyMEe1NC=>
MKN 45 MVvLbY5ie2ViQYPzZZk> MXOxJIg> MomySG1UVw>? MWLJcohq[mm2aX;uJI9nKGNvTXX0JJBpd3OyaH;yfYxifGmxbjD3bZRpKEmFNUCgc4YhOC5yMjFOwG0> Mn;UNlQ6ODB5NUC=
A549 NV23bHplS3m2b4TvfIlkKEG|c3H5 MoXJOFghcA>? NEDsc4VFVVOR M4fhRWlEPTBib3[gOE4xQDRizszN MlLiNlQ6ODB6M{C=
NCI-H1975 Mn;sR5l1d3SxeHnjJGF{e2G7 MUK0PEBp NHLOe4tFVVOR M3zaWmlEPTBib3[gO{42PTFizszN MnjxNlQ6ODB6M{C=
NCI-H1993 MYLDfZRwfG:6aXOgRZN{[Xl? MU[0PEBp NILQT5ZFVVOR MVTJR|UxKG:oIECuNFYyKM7:TR?= NH;KRWQzPDlyMEizNC=>
NCI-H1993 MXHBdI91d3OrczDBd5NigQ>? MYqxJO69VQ>? NIfidmIzPCCq MWXEUXNQ M4T6WYRw\XNibn;0JIlv\HWlZTDhdI9xfG:|aYO= NFvEbpMzPDlyMEizNC=>
NIH-3T3 NH\0[FJEgXSxdH;4bYMhSXO|YYm= MoXPOFghcA>? MYrEUXNQ MV\JR|UxKG:oIECuN|Y1KM7:TR?= M{TuN|I1QTByOEOw
EBC1 M{\RZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LNZlczKGh? MmPuSG1UVw>? MnToTWM2OCCxZjCwMlAxPjlizszN MmrSNlQ6ODB6M{G=
KARPAS299 MluxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MorJO|IhcA>? NFL3ZYhFVVOR MV7JR|UxKG:oIECuNkDPxE1? NUDUeoN1OjR7MEC4N|E>
NB1 NGPL[29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTlzLkm4JI5O MlfhV2FPT0WU
NCI-SNU-5 NV\yXVkxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PmZmlEPTB;MUC1Mlc2KG6P MXnTRW5ITVJ?
SR NGrjfFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLxO4RKSzVyPUGyOk4{OSCwTR?= MkPaV2FPT0WU
SF539 M3rMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTJyND6yOEBvVQ>? MlrGV2FPT0WU
SU-DHL-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPkRVlKSzVyPUOzOk45OiCwTR?= MkXrV2FPT0WU
SCC-3 M3vQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofLTWM2OD1|NU[uO|Yhdk1? MoW1V2FPT0WU
DEL NY[xeFZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlTrTWM2OD1|NkmuPUBvVQ>? NX;XbHdCW0GQR1XS
CTV-1 NGnrSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3q3OmlEPTB;NUm2MlQ5KG6P NWTJ[ZBqW0GQR1XS
EM-2 NVX5XZJ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3lTWM2OD14MEGuN|Qhdk1? NGW1R3RUSU6JRWK=
MHH-CALL-2 NV7sdmgxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfk[HRKSzVyPU[4Nk42PyCwTR?= NHTKT5VUSU6JRWK=
KM12 NEXjboNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm\XTWM2OD15ME[uPUBvVQ>? MojiV2FPT0WU
KINGS-1 Mki3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTd2OT63OUBvVQ>? NVHOR3V6W0GQR1XS
MEG-01 M3fS[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonQTWM2OD16NUeuOlYhdk1? NFnFd29USU6JRWK=
BV-173 NGSzcodIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTFwMEW5PVch|ryP NEW1WYxUSU6JRWK=
LAMA-84 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUK0eIhPUUN3ME2xMlM5Ojh{IN88US=> NIH4eGdUSU6JRWK=
KARPAS-299 M4DKSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\vXWlEPTB;MT60NFg3OSEQvF2= NX3rRVlPW0GQR1XS
K-562 NYfadnl1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUP2cW9NUUN3ME2xMlczOjZ7IN88US=> M1vQXXNCVkeHUh?=
SK-LMS-1 M3TkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NILhN4NKSzVyPUGuO|Y5PjdizszN MUjTRW5ITVJ?
MOLT-16 NVnVfFNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\DTWM2OD1zLkm1OVc2KM7:TR?= NGXNS4hUSU6JRWK=
CMK NXXHOHFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmD6TWM2OD1zLkm2NVU6KM7:TR?= MknCV2FPT0WU
ST486 M4[xNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVr5WJV1UUN3ME2yMlQ{ODd|IN88US=> NWnjVoVzW0GQR1XS
CI-1 MnzMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTJwNEm2OVkh|ryP M1vqSHNCVkeHUh?=
KP-N-RT-BM-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHUd5NWUUN3ME2yMlcxOTJ{IN88US=> NUizTpFYW0GQR1XS
ALL-PO NVq4OZVrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPiTWM2OD1|LkG4NlA4KM7:TR?= MX;TRW5ITVJ?
KS-1 M4LCdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DGUGlEPTB;Mz6yNVIzPSEQvF2= NILVZlFUSU6JRWK=
Becker M1X2O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4e0ZWlEPTB;ND6yN|k{KM7:TR?= MkDIV2FPT0WU
GDM-1 M2rCXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TqSGlEPTB;ND6yOFYyPyEQvF2= M37sSXNCVkeHUh?=
BC-1 M2LWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljOTWM2OD12LkS5Nlc4KM7:TR?= Ml;VV2FPT0WU
NB14 M1[5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUHHSWZHUUN3ME20Mlg{PTJ2IN88US=> Mk\PV2FPT0WU
NOS-1 M2\kRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTVwM{O4O|Qh|ryP M4TzcXNCVkeHUh?=
MZ1-PC MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2Tod2lEPTB;NT64NlE2OSEQvF2= NV72bIZGW0GQR1XS
A498 M3fRVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;kRWxKSzVyPU[uNFg1PzNizszN NXTG[|hxW0GQR1XS
EW-16 MnzhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXuTWM2OD14LkO3O|c{KM7:TR?= MULTRW5ITVJ?
NALM-6 NX\1VVJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYrabZloUUN3ME22MlY5Ozh5IN88US=> NXjGZnAxW0GQR1XS
EB-3 Mn;xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPrVldKSzVyPUeuNFczOzNizszN NILkNVNUSU6JRWK=
697 M4\2bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXTTWM2OD17LkK0N|I6KM7:TR?= NED1ToRUSU6JRWK=
Ramos-2G6-4C10 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXTHepNwUUN3ME25MlU6QDR{IN88US=> MkLJV2FPT0WU
KNS-81-FD MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jMRmlEPTB;OT62PVY2OyEQvF2= MVrTRW5ITVJ?
HUTU-80 NHjj[|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfyVIhJUUN3ME25Mlc1PjR{IN88US=> NUT5NllKW0GQR1XS
LS-411N M3;2SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXL6eXhLUUN3ME2xNE4xPTZ5IN88US=> MmDLV2FPT0WU
RPMI-8402 NIf2T5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rqfmlEPTB;MUCuNVE3KM7:TR?= NETWNlRUSU6JRWK=
KU812 NVPkRpFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDyS41CUUN3ME2xNE4zQTlzIN88US=> M{DiUXNCVkeHUh?=
EW-1 MoHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3K2bGlEPTB;MUCuOFQzPSEQvF2= MVXTRW5ITVJ?
HC-1 Mo[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M364XmlEPTB;MUCuOFg1PCEQvF2= MnPYV2FPT0WU
NB69 M2fBRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIq1cppKSzVyPUGwMlUxPDNizszN MWPTRW5ITVJ?
MFH-ino NV3nU4piT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DJRWlEPTB;MUCuPFMxOyEQvF2= MmPSV2FPT0WU
CCRF-CEM NVHhRZRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3we2Q2UUN3ME2xNU42QTdizszN MULTRW5ITVJ?
SK-N-DZ NVnrSZV7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTF{LkC0N|Yh|ryP NFLh[2VUSU6JRWK=
NCI-H720 Mni4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzFZpZpUUN3ME2xNk4yPzB3IN88US=> M3TrTHNCVkeHUh?=
HCC1187 NHTqbohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnP4TWM2OD1zMj6yNFQyKM7:TR?= NFzXT3JUSU6JRWK=
IST-SL2 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkO0TWM2OD1zMj60PFczKM7:TR?= NFzseWhUSU6JRWK=
KE-37 NFHwOm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHUbXFKSzVyPUGyMlc6PjZizszN NW\3ZY5DW0GQR1XS
HCC1599 MmfIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1rLNmlEPTB;MUKuPVA3QSEQvF2= MmntV2FPT0WU
A4-Fuk MkjtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{PsVGlEPTB;MUKuPVU5PiEQvF2= MX;TRW5ITVJ?
NKM-1 MlviS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\RflJKSzVyPUGzMlI6OjVizszN MkX6V2FPT0WU
BE-13 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT2TWM2OD1zMz63PVg6KM7:TR?= MXPTRW5ITVJ?
MV-4-11 NXH2fZRFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfhTWM2OD1zND6wN|I1KM7:TR?= M4P3[HNCVkeHUh?=
OPM-2 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3zCcWlEPTB;MUSuOFA5PSEQvF2= MYPTRW5ITVJ?
KARPAS-422 NF72XXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXTJR|UxRTF2LkWxNlYh|ryP NWHDPJBMW0GQR1XS
RPMI-8226 M1XSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nyT2lEPTB;MUSuPFkyPSEQvF2= M3TnXnNCVkeHUh?=
KARPAS-45 NXj2TpZRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPZTWM2OD1zNT63O|E3KM7:TR?= NYPYSZZ6W0GQR1XS
SK-PN-DW NHO5PJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTF3Lki2N|Eh|ryP MnPkV2FPT0WU
LC-2 M{G0[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXZbnF[UUN3ME2xOk4yPTB4IN88US=> NWHZT2dLW0GQR1XS
NCI-H1648 NXrL[mM2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLrNphKSzVyPUG2MlI2PCEQvF2= NELwV49USU6JRWK=
RL95-2 M4HKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;oPGlEPTB;MU[uN|k4QCEQvF2= NIeyb3VUSU6JRWK=
KNS-42 M3\GWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUG0SVY2UUN3ME2xOk44Ojd2IN88US=> MYfTRW5ITVJ?
RPMI-6666 MkiyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3Lyc2lEPTB;MU[uPVIyOSEQvF2= NX3uSnFNW0GQR1XS
SIG-M5 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmSzTWM2OD1zNz6xPVA{KM7:TR?= NVzqT4k{W0GQR1XS
VA-ES-BJ NHKyUHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDXWY1KSzVyPUG3Mlc1PTFizszN NITnXoFUSU6JRWK=
MONO-MAC-6 MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTF5LkmzNVIh|ryP NHjqfmpUSU6JRWK=
LAN-6 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf0dYJKSzVyPUG4Mlc2PTdizszN NVjafJViW0GQR1XS
A388 M2ThSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTF7LkOwOVkh|ryP Mne5V2FPT0WU
SK-NEP-1 NWDP[YJtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3wOIJKSzVyPUKwMlIyOzJizszN M3LQRnNCVkeHUh?=
TE-10 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3W2T2lEPTB;MkCuOVIzOSEQvF2= NGXWWGxUSU6JRWK=
HL-60 NGTvPYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH7qZZFKSzVyPUKwMlkxQTlizszN NUDwRZBQW0GQR1XS
MC116 NFSyT3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4PPO2lEPTB;MkGuO|IzOSEQvF2= M4TTdXNCVkeHUh?=
SW962 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLqU4ZDUUN3ME2yNU44QTF3IN88US=> M2[zPHNCVkeHUh?=
NOMO-1 M3LXNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVrmU4hWUUN3ME2yNk43PTZ2IN88US=> Mm[2V2FPT0WU
CTB-1 NIHlfGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml;sTWM2OD1{Mj64OlcyKM7:TR?= MkfHV2FPT0WU
MRK-nu-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjre4RKSzVyPUKyMlkxPzRizszN MkXXV2FPT0WU
GR-ST MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnaTWM2OD1{Mz63OkDPxE1? NEX0doVUSU6JRWK=
HH NHXxW2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTJ2LkCwN{DPxE1? MV\TRW5ITVJ?
NCI-H1963 M2jVbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTJ2LkC3PFIh|ryP NXeyOlM1W0GQR1XS
QIMR-WIL MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\aNGE3UUN3ME2yOE45Pzd{IN88US=> NGnXfXpUSU6JRWK=
CGTH-W-1 NED4OXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJ3LkC3NlMh|ryP NYTxNHdUW0GQR1XS
LP-1 NXPv[|hYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF7uTndKSzVyPUK1MlY2PTFizszN MWfTRW5ITVJ?
NCI-H748 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH\rd3FKSzVyPUK2MlUyOzdizszN NIHzboZUSU6JRWK=
PF-382 M3XxW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DjfWlEPTB;MkeuNlIzOyEQvF2= MYnTRW5ITVJ?
ATN-1 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF2xWY9KSzVyPUK3MlM4OzJizszN M4\FZ3NCVkeHUh?=
L-540 NWD0dpg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHkTWM2OD1{Nz62OFU6KM7:TR?= MX3TRW5ITVJ?
LXF-289 NWnmZnh3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LWeGlEPTB;MkeuO|UyQSEQvF2= NUmx[YQzW0GQR1XS
LS-513 M1S4SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLmTWM2OD1{OD6xPFA4KM7:TR?= MXrTRW5ITVJ?
NCI-H1581 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUCzXZhFUUN3ME2zNE4{QTd4IN88US=> M4Xhe3NCVkeHUh?=
ES6 M1rXOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;scmlEPTB;M{CuOlg6QSEQvF2= NYDW[WhuW0GQR1XS
SW982 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGOyNlhKSzVyPUOwMlg2PjZizszN MXvTRW5ITVJ?
DOHH-2 NEe3XplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1z0XWlEPTB;M{GuOVg6OyEQvF2= Mke4V2FPT0WU
DB NGnGV5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTtRWFKSzVyPUOzMlk1OzFizszN Mk\VV2FPT0WU
MPP-89 NG\n[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVPJR|UxRTN2LkG3OVYh|ryP Mon6V2FPT0WU
LB831-BLC NUXGNVZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHlfVF[UUN3ME2zOE42OTh2IN88US=> MXHTRW5ITVJ?
NB5 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjDTWM2OD1|ND64OVM2KM7:TR?= NG\tPIFUSU6JRWK=
GB-1 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MonKTWM2OD1|NT6wOFY6KM7:TR?= MnjOV2FPT0WU
TE-15 M1\JdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkX3TWM2OD1|NT6yNlM5KM7:TR?= M3z0[XNCVkeHUh?=
LC4-1 M3e2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN3LkO4OFch|ryP MlXaV2FPT0WU
NCI-H747 M2LmS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFHlVVZKSzVyPUO2MlE{PjlizszN M3rpfnNCVkeHUh?=
NTERA-S-cl-D1 Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkezTWM2OD1|OD63N|Q4KM7:TR?= MkC3V2FPT0WU
SK-MM-2 NUWyOG5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXf1fYF3UUN3ME20NE4yOTR4IN88US=> MmWyV2FPT0WU
TGW NILH[FlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkXGTWM2OD12MT6wOVY{KM7:TR?= MXnTRW5ITVJ?
ONS-76 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTR{LkS4PFMh|ryP MXHTRW5ITVJ?
CPC-N M3XBSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTR{Lkm5O|Eh|ryP NF;iV4FUSU6JRWK=
ES4 NF\pdVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEP2d4FKSzVyPUS0MlQyPTNizszN MnvjV2FPT0WU
Daudi M4nm[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\Je4dKSzVyPUS1MlA5OjdizszN MnjTV2FPT0WU
MOLT-4 MlTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnNNVAyUUN3ME20OU4xQDV|IN88US=> M{iwWXNCVkeHUh?=
HT-144 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vUe2lEPTB;NE[uO|I3KM7:TR?= NXfrSpVDW0GQR1XS
SW872 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33PemlEPTB;NEiuNVk{OyEQvF2= NV\RcohKW0GQR1XS
D-283MED MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTtTWM2OD12OD6zOVQzKM7:TR?= MV;TRW5ITVJ?
NCI-H2126 M{GxWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDnT29KSzVyPUS4Mlg1PzZizszN NFjpZW9USU6JRWK=
NCI-SNU-16 NFqwN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR7LkKxOFMh|ryP MkXCV2FPT0WU
CESS MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXYOmlKUUN3ME20PU42ODh6IN88US=> M2L2ZXNCVkeHUh?=
A101D M2fRN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3LGR2lEPTB;NEmuPVc{PiEQvF2= NYq3[HV2W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo In the GTL-16 model, PF-2341066 reveals the ability to cause marked regression of large established tumors (>600 mm3) in both the 50 mg/kg/day and 75 mg/kg/day treatment cohorts, with a 60% decrease in mean tumor volume over the 43-day administration schedule. In an another study, PF-2341066 displays the ability to completely inhibits GTL-16 tumor growth for >3 months, with only 1 of 12 mice exhibiting a significant increase in tumor growth over the 3-month treatment schedule at 50 mg/kg/day. In the NCI-H441 NSCLC model, a 43% decrease in mean tumor volume is observed at 50 mg/kg/day during the 38-day PF-2341066 administration cycle. In the Caki-1 RCC model, a 53% decrease in mean tumor volume is observed to be associated with decreased volume of each tumor by at least 30% at 50 mg/kg/day during the 33-day PF-2341066 administration cycle. PF-2341066 also reveals near-complete prevention of the growth of established tumors at 50 mg/kg/day in the U87MG glioblastoma or PC-3 prostate carcinoma xenograft models, with 97% or 84% inhibition on the final study day, respectively. In contrast, PF-2341066 p.o. given at 50 mg/kg/day does not significantly inhibit tumor growth in the MDA-MB-231 breast carcinoma model, or the DLD-1 colon carcinoma model. A significant dose-dependent reduction of CD31–positive endothelial cells is observed at 12.5 mg/kg/day, 25 mg/kg/day, and 50 mg/kg/day in GTL-16 tumors, indicating that inhibition of MVD shows a dose-dependent correlation to antitumor efficacy. PF-2341066 displays a significant dose-dependent reduction of human VEGFA and IL-8 plasma levels in both the GTL-16 and U87MG models. Marked inhibition of phosphorylated c-Met, Akt, Erk, PLCλ1, and STAT5 levels is observed in GTL-16 tumors following p.o. administration of PF-2341066.[1] P.o. administration of PF-2341066 to severe combined immunodeficient-Beige mice bearing Karpas299 ALCL tumor xenografts leads to dose-dependent antitumor efficacy with complete regression of all tumors at the 100 mg/kg/d dose within 15 days of initial compound administration. In addition, inhibition of key NPM-ALK signaling mediators, including phospholipase C-gamma, signal transducers and activators of transcription 3, extracellular signal-regulated kinases, and Akt by PF-2341066 are observed at concentrations or dose levels, which correlated with inhibition of NPM-ALK phosphorylation and function.[2] PF-2341066 prevents osteosarcoma behavior associated with primary tumor growth (eg, proliferation and survival) as well as metastasis (eg, invasion and clonogenicity). In nude mice treated with PF-2341066 via oral gavage, the growth and associated osteolysis and extracortical bone matrix formation of osteosarcoma xenografts are prevented by PF-2341066.[3] Treatment of c-MET-amplified GTL-16 xenografts with 50 mg/kg PF-2341066 elicits tumor regression that is associated with a slow reduction in 18F-FDG uptake and decreases expression of the glucose transporter 1, GLUT-1.[4]

Protocol

Kinase Assay:[1]
+ Expand

Cellular kinase phosphorylation ELISA assays:

Cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 h. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 min. After incubation of cells with PF-2341066 for 1 h and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4°C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3′,5,5′-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
Cell Research:[1]
+ Expand
  • Cell lines: GTL-16 gastric carcinoma cells and T47D breast carcinoma cells
  • Concentrations: 0-256 nM
  • Incubation Time: 1 hour
  • Method: Cells including GTL-16 gastric carcinoma cells and T47D breast carcinoma cells are seeded in 96-well plates in media supplemented with 10% fetal bovine serum (FBS) and transferred to serum-free media [with 0.04% bovine serum albumin (BSA)] after 24 hours. In experiments investigating ligand-dependent RTK phosphorylation, corresponding growth factors are added for up to 20 minutes. After incubation of cells with PF-2341066 for 1 hour and/or appropriate ligands for the designated times, cells are washed once with HBSS supplemented with 1 mM Na3VO4, and protein lysates are generated from cells. Subsequently, phosphorylation of selected protein kinases is assessed by a sandwich ELISA method using specific capture antibodies used to coat 96-well plates and a detection antibody specific for phosphorylated tyrosine residues. Antibody-coated plates are (a) incubated in the presence of protein lysates at 4 °C overnight; (b) washed seven times in 1% Tween 20 in PBS; (c) incubated in a horseradish peroxidase–conjugated anti–total-phosphotyrosine (PY-20) antibody (1:500) for 30 min; (d) washed seven times again; (e) incubated in 3,3,5,5-tetramethyl benzidine peroxidase substrate to initiate a colorimetric reaction that is stopped by adding 0.09 N H2SO4; and (f) measured for absorbance in 450 nm using a spectrophotometer.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 9 mg/mL (19.98 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 5% DMSO+30% PEG 300+dd H2O 5mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 450.34
Formula

C21H22Cl2FN5O

CAS No. 877399-52-5
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03052608 Not yet recruiting Carcinoma, Non-Small-Cell Lung Pfizer March 2017 Phase 3
NCT02838420 Recruiting Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer Hoffmann-La Roche August 2016 Phase 3
NCT02836847 Recruiting Cholangiocarcinoma of the Extrahepatic Bile Duct|Gallbladder Cancer Shanghai Jiao Tong University School of Medicine|Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Eastern Hepatobiliary Surgery Hospital|Huashan Hospital July 2016 Phase 2
NCT02946359 Recruiting Lung Adenocarcinoma Metastatic Chinese PLA General Hospital July 2016 Phase 2
NCT02679170 Recruiting Non-Small Cell Lung Cancer Pfizer June 2016 --
NCT02767804 Recruiting Non-small Cell Lung Cancer Xcovery Holding Company, LLC June 2016 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

c-Met Signaling Pathway Map

c-Met Inhibitors with Unique Features

Related c-Met Products

Tags: buy Crizotinib (PF-02341066) | Crizotinib (PF-02341066) supplier | purchase Crizotinib (PF-02341066) | Crizotinib (PF-02341066) cost | Crizotinib (PF-02341066) manufacturer | order Crizotinib (PF-02341066) | Crizotinib (PF-02341066) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID